Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales

Core Insights - Bausch Health Companies Inc. (BHC) reported better-than-expected fourth-quarter results, with shares gaining 2.36% and 7.8% in aftermarket trading [1][2] - Adjusted earnings per share (EPS) of $1.15 exceeded the Zacks Consensus Estimate of $1.12, remaining flat year over year [1][2] - Total revenues reached $2.56 billion, a 6% increase year over year, surpassing the Zacks Consensus Estimate by 1.89% [2] Revenue Breakdown - Salix segment revenues were $634 million, up 9% year over year, driven by strong demand for Xifaxan, which saw a 16% increase [3][4] - International revenues totaled $279 million, down 4% year over year, missing estimates due to declines in Latin America [5] - Solta Medical reported revenues of $138 million, a 34% increase year over year, significantly beating estimates [6] - Bausch + Lomb revenues amounted to $1.3 billion, up 9% year over year, also exceeding estimates [8] Annual Performance - For the full year, BHC reported revenues of $9.62 billion, a 10% increase year over year, surpassing the Zacks Consensus Estimate [9] - Adjusted EPS for the year was $3.75, beating the Zacks Consensus Estimate of $3.73 [9] Pipeline Development - The phase II study on amiselimod for ulcerative colitis has completed enrollment, with a phase III study protocol submitted to the FDA [10] - Phase III studies for rifaximin in hepatic encephalopathy are ongoing, with top-line results expected by early 2026 [11] - The Clear and Brilliant Touch program for skin rejuvenation is advancing, with multiple international approvals received [12] Future Guidance - BHC expects 2025 revenues to range from $9.9 billion to $10.15 billion, with Bausch + Lomb revenues anticipated between $4.95 billion and $5.05 billion [13] Financial Strategy - BHC's subsidiary entered a financing commitment for a senior secured credit facility of up to $700 million, aimed at repaying 2025 and 2026 debt obligations [15][16]